🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Echocardiography-Based Predictors of Outcomes in Hospitalized Patients With Decompensated Heart Failure (ECHO-DECOMP)

Recruitingn/aAges 18 Years - anyAllIstanbul University - Cerrahpasa
NCT07439159 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Acute decompensated heart failure is a leading cause of hospitalization and is associated with high morbidity and mortality. Early risk stratification in this population is crucial for guiding treatment strategies and predicting short- and long-term clinical outcomes. Transthoracic echocardiography is routinely performed in patients hospitalized with acute decompensated heart failure and provides comprehensive information regarding cardiac structure and function. However, the prognostic value of detailed echocardiographic parameters obtained before the initiation of intravenous diuretic therapy has not been fully clarified. The objective of this prospective study is to evaluate the prognostic significance of transthoracic echocardiographic findings obtained at hospital admission, prior to intravenous diuretic therapy, in patients hospitalized with acute decompensated heart failure. The

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adults aged ≥18 years. * Hospitalization due to acute decompensated heart failure. * Intravenous diuretic therapy deemed necessary by the treating cardiologist. * Predominant left-sided heart failure. * Provision of written informed consent prior to participation. Exclusion Criteria: * Severe anemia (hemoglobin \<7 g/dL). * Requirement for renal replacement therapy, including hemodialysis or peritoneal dialysis, or being listed for kidney transplantation. * Severe primary mitral regurgitation. * Severe aortic stenosis. * Severe aortic regurgitation. * Severe primary tricuspid regurgitation. * Primary right heart failure. * Heart failure secondary to congenital heart disease. * History of mitral valve replacement. * History of aortic valve replacement. * History of bioprosthetic valve replacement. * History of transcatheter aortic valve implantation. * Presence of active malignancy. * Failure to provide written informed consent. * Inability to perform transthoracic echocardiography prior to intravenous diuretic therapy for any reason.
💊

What it tests

  • Not listed
📍

Where

1 site
Istanbul University Cerrahpaşa Institute of Cardiology
Istanbul, Turkey (Türkiye)
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy